Bayer plc

Bayer House, Strawberry Hill, Newbury, Berkshire, RG14 1JA
Telephone: +44 (0)1635 563 000
Fax: +44 (0)1635 563 393
WWW: http://www.bayer.co.uk

Summary of Product Characteristics last updated on the eMC: 13/05/2011
SPC Femodene ED

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 13/05/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 6. 6 - Instructions for use, handling and disposal
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   19-Jan-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

The key change is:

Section 6.6

 

has been updated in line with EC Guideline and now states 'No special requirements

 

Updated on 28/05/2008 and displayed until 13/05/2011
Reasons for adding or updating:
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-May-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



All updates are due to change of ownership, from Schering Healthcare Ltd to Bayer Plc effective from 1 May 2008.

Section 7: MAH now Bayer plc
Section 8: Licence number is now PL 00010/ 0530
Section 9: Date of first authorisation is now 1 May 2008
Section 10: Revision date is now 1 May 2008 

Updated on 25/02/2005 and displayed until 28/05/2008
Reasons for adding or updating:
  • Change to section 10 (date of (partial) revision of the text
  • Change from the BAN of the active substance to the rINN
Updated on 27/06/2002 and displayed until 25/02/2005
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 10 (date of (partial) revision of the text
Updated on 17/01/2002 and displayed until 27/06/2002
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 09/01/2002 and displayed until 17/01/2002
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
Updated on 10/07/2001 and displayed until 09/01/2002
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 29/08/2000 and displayed until 10/07/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 29/08/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   ethinylestradiol
   gestodene